Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
Insulet (PODD) Stock Price & Analysis
721 Followers
PODD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$125.82 - $284.60
Previous Close$195.03
Volume653.93K
Average Volume (3M)811.04K
Market Cap
$13.66B
Enterprise Value$14.31B
Total Cash (Recent Filing)$751.20M
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)59.0
Beta0.94
Next Earnings
Aug 08, 2024EPS Estimate
$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding70,039,511
10 Day Avg. Volume689,404
30 Day Avg. Volume811,038
Standard Deviation0.12
R-Squared0.24
Alpha0.00111
Financial Highlights & Ratios
Price to Book (P/B)22.32
Price to Sales (P/S)8.42
Price to Cash Flow (P/CF)40.80
P/FCF Ratio48.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.04
Enterprise Value/Gross Profit12.34
Enterprise Value/Ebitda104.84
Forecast
1Y Price Target
$233.14Price Target Upside19.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Insulet News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyResults from PODD's SECURE-T2D pivotal trial revealed glycemic improvements for type 2 patients using Omnipod 5 compared to prior treatment of insulin injections or pump therapy.
Market LeadershipInsulet's Omnipod 5 (O5) has secured the leading share position in the Type 2 intensive insulin segment of the pump market by a wide margin, mainly due to its discrete footprint and exclusivity in the pharmacy channel.
Product InnovationThe company is making progress in its next generation algorithms with Smart Adjust 2.0 and Evolution and will start clinical studies soon.
Bears Say
Legal IssuesThe US court overseeing PODD's case vs. EOFlow lifted its preliminary injunction forbidding EOFlow from developing and commercializing its patch pump.
Market CompetitionEOFlow produces a similar insulin pump called the EOPatch 2, which has been approved for sale in select Asian and European markets.
New Patient StartsNew US patient starts were down year-over-year.
---
Ownership Overview
17.73% Insiders
51.27% Mutual Funds
24.72% Other Institutional Investors
6.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $125.82 and its highest was $284.60 in the past 12 months.
What is Insulet’s market cap?
Currently, no data Available
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on May 09, 2024. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.401 by $0.329.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is $0.56.
How many shares outstanding does Insulet have?
Insulet has 70,039,510 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $0.73 in its last earnings report, beating expectations of $0.401. Following the earnings report the stock price went down -6.551%.
Which hedge fund is a major shareholder of Insulet?
Among the largest hedge funds holding Insulet’s share is D1 Capital Partners LP. It holds Insulet’s shares valued at 171M.
---
Insulet Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$233.14 (19.54% Upside)
$233.14 (19.54% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 77%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 257.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.23%
12-Months-Change
Fundamentals
Return on Equity
36.18%
Trailing 12-Months
Asset Growth
14.63%
Trailing 12-Months
Company Description
Insulet
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
---
PODD Company Deck
---
PODD Earnings Call
Q1 2024
0:00 / 0:00
---
PODD Revenue Breakdown
73.71% U.S. Omnipod
24.16% International Omnipod
2.12% Drug Delivery
---
PODD Stock 12 Month Forecast
Average Price Target
$233.14
▲(19.54% Upside)
Technical Analysis
Best Analysts Covering PODD
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+23.38%
reiterated a buy rating 29 days ago
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +23.38% per trade.
---